AptaBio Therapeutics Inc. (293780.KQ)
KRW 7880.0
(4.65%)
KRW 7880.0
(4.65%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 16.45 Billion KRW | 81.28% |
| 2022 | 9.07 Billion KRW | -19.35% |
| 2021 | 11.24 Billion KRW | 83.25% |
| 2020 | 6.13 Billion KRW | -23.99% |
| 2019 | 8.07 Billion KRW | 67.99% |
| 2018 | 4.8 Billion KRW | 105.7% |
| 2017 | 2.33 Billion KRW | 51.18% |
| 2016 | 1.54 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.15 Billion KRW | 7.45% |
| 2024 Q1 | 3.05 Billion KRW | -42.57% |
| 2023 Q2 | 2.87 Billion KRW | -17.4% |
| 2023 Q3 | 4.09 Billion KRW | 42.34% |
| 2023 Q4 | 5.31 Billion KRW | 29.81% |
| 2023 Q1 | 3.48 Billion KRW | 36.33% |
| 2023 FY | 16.44 Billion KRW | 81.28% |
| 2022 FY | 9.07 Billion KRW | -19.35% |
| 2022 Q4 | 2.55 Billion KRW | 51.12% |
| 2022 Q3 | 1.68 Billion KRW | -39.22% |
| 2022 Q2 | 2.77 Billion KRW | 77.54% |
| 2022 Q1 | 1.56 Billion KRW | -45.41% |
| 2021 FY | 11.24 Billion KRW | 83.25% |
| 2021 Q3 | 2.59 Billion KRW | -22.53% |
| 2021 Q2 | 3.34 Billion KRW | 37.23% |
| 2021 Q1 | 2.43 Billion KRW | -1.37% |
| 2021 Q4 | 2.86 Billion KRW | 10.61% |
| 2020 Q1 | 1.62 Billion KRW | -36.24% |
| 2020 Q4 | 2.47 Billion KRW | 151.09% |
| 2020 FY | 6.13 Billion KRW | -23.99% |
| 2020 Q3 | 984.82 Million KRW | 70.68% |
| 2020 Q2 | 576.99 Million KRW | -64.44% |
| 2019 Q4 | 2.54 Billion KRW | 2.74% |
| 2019 FY | 8.07 Billion KRW | 67.99% |
| 2019 Q3 | 2.47 Billion KRW | 104.89% |
| 2019 Q2 | 1.2 Billion KRW | 0.0% |
| 2018 Q4 | 2.41 Billion KRW | 220.04% |
| 2018 Q3 | 755.13 Million KRW | -56.04% |
| 2018 Q2 | 1.71 Billion KRW | 0.0% |
| 2018 FY | 4.8 Billion KRW | 105.7% |
| 2017 FY | 2.33 Billion KRW | 51.18% |
| 2016 FY | 1.54 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 102.52 Billion KRW | 83.954% |
| CMG Pharmaceutical Co., Ltd. | 37.86 Billion KRW | 56.553% |
| Celltrion Pharm, Inc. | 80.93 Billion KRW | 79.673% |
| Huons Global Co., Ltd. | 294.87 Billion KRW | 94.421% |
| DongKook Pharmaceutical Co., Ltd. | 338.16 Billion KRW | 95.135% |
| Enzychem Lifesciences Corporation | 18.7 Billion KRW | 12.041% |
| Humedix Co., Ltd. | 33.04 Billion KRW | 50.211% |
| Boditech Med Inc. | 47.05 Billion KRW | 65.034% |
| EuBiologics Co., Ltd. | 24.95 Billion KRW | 34.086% |
| FutureChem Co.,Ltd | 9.16 Billion KRW | -79.486% |
| Huons Co., Ltd. | 226.14 Billion KRW | 92.725% |
| BNC Korea Co., Ltd. | 25.19 Billion KRW | 34.712% |